A PROSPECTIVE RANDOMIZED STUDY OF TC AND MVP IN ADVANCED NON-SMALL CELL LUNG CANCER

ObjectiveTo evaluate the response,adverse effects and life span of TC and NVP therapeutic regimens for non-small cell lung cancer(NSCLC).MethodsSixty-eight patients with advanced NSCLC were randomized into two groups: TC group(n=34,paclitaxel 175 mg/m~2,d1;carboplatin 300 mg/m~2,d2) and MVP group(n=34,mitomycin C 6-8 mg/ m~2,d1;vindesine 2-3 mg/m~2 d1 and d8;cisplatin 70-80 mg/m~2,d1 and d2).All patients received two to four courses of chemotherapy. ResultsThe overall response was 62%(21/34) in TC group and 26% (9/34) in MVP group.There was one complete response,20 partial responses in TC group;one complete response,and eight partial response in MVP group.TC regimen appeared to have a higher objective response with statistical difference between two regimens(χ~2=8.589,P0.05).Major side effects were myelosuppression and nausea/vomiting,especially grade Ⅲ,Ⅳnausea/vomiting were significantly higher in MVP than TC(26% and 3%,χ~2=7.503,P0.01).Grade Ⅲ,Ⅳ myelosuppression was higher in MVP than TC,but with no statistical significance existed in the two groups.Median survival time was 10 months vs eight months,and 1-,2-,3-year survival rates were 47% vs 20%((χ~2=)5.321,P0.05),17% vs 6%,2% vs 0,for TC and MVP,respectively.ConclusionTC regimen has a higher response rate and longer survival time,less nausea /vomiting and myelosuppression than MVP regimen.TC regimen is a safe and active regimen for advanced non-small cell lung cancer.